Akmal M. 2001. Hemodialysis in diabetic patients. American Journal of Kidney Diseases 38: S195-199.
Albu DI, Wang Z, Huang KC, Wu J, Twine N, Leacu S, Ingersoll C, Parent L, Lee W, Liu D, Wright-Michaud R, Kumar N, Kuznetsov G, Chen Q, Zheng W, Nomoto K, Woodall-Jappe M, Bao X. 2017. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology 2017 6: e1338239.
Berl T. 2009. Review: renal protection by inhibition of the renin-angiotensin- aldosterone system. Journal of the Renin-Angiotensin-Aldosterone System 10: 1-8.
Betz B, Conway BR. 2014. Recent advances in animal models of diabetic nephropathy. Nephron. Experimental nephrology 126: 191–195.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine 345: 861-869.
Breyer MD, Jacobson HR, Breyer RM. 1996. Functional and molecular aspects of renal prostaglandin receptors. Journal of the American Society of Nephrology 7: 8-17.
Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. 2001. Prostanoid receptors: subtypes and signaling. Annual Review of Pharmacology 41: 661-690.
Clive DM, Stoff JS. 1984. Renal syndromes associated with nonsteroidal antiinflammatory drugs. The New England Journal of Medicine 310: 563–572.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. 2007. Prevalence of chronic kidney disease in the United States. The Journal of the American Medical Association 298: 2038-2047.
Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. 2008. Kidney International 74: 867-872.
Fioretto P, Dodson PM, Ziegler D, Rosenson RS. 2010. Residual microvascular risk in diabetes: unmet needs and future directions. Nature Reviews. Endocrinology 6:19- 25.
Fogo AB. Mechanisms of progression of chronic kidney disease. 2007. Pediatric Nephrology 22: 2011-2022.
Friis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, Bie P, Skøtt O, Jensen BL. 2013. Regulation of renin secretion by renal juxtaglomerular cells. Pflügers Archiv 465: 25-37.
Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, Collins AJ. 2005. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. Journal of the American Society of Nephrology 16: 3736-3741.
Hall PM. 2006. Prevention of progression in diabetic nephropathy. Diabetes Spectrum 19: 18-24.
Hattori K, Tanaka A, Fujii N, Takasugi H, Tenda Y, Tomita M, Nakazato S, Nakano K, Kato Y, Kono Y, Murai H, and Sakane K. 2005. Discovery of diphenyloxazole and Nä-z-ornithine derivatives as highly potent and selective human prostaglandin EP4 receptor antagonists. Journal of Medicinal Chemistry 48: 3103-3106.
Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. 2012. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nature Reviews Nephrology 21: 293-300.
Hill CJ, Fogarty DG. 2012. Changing trends in end-stage renal disease due to diabetes in the United Kingdom. Journal of Renal Care 38: 12-22.
Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. 2012. Pediatric Nephrology 27: 901-909.
Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege H, Parving HH, Brenner BM, Shahinfar S, Heerspink HL. 2011. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney International 80: 282–287.
Jensen BL, Schmid C, Kurtz A 1996. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. American Journal of Physiology 271: F659-669.
Jian DY, Chao YW, Ting CH, Huang SW, Chang CF, Juan CC, Chen JY. Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. 2013. European Journal of Pharmacology 709: 85-92.
Kasai K, Sato S, Suzuki K. 2001. A novel prostaglandin E receptor subtype agonist, ONO-4819, attenuates acute experimental liver injury in rats. Hepatology research 21: 252-260.
KDIGO Board Members 2013. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 3: 19–62
Kikkawa R, Haneda M, Sakamoto K, Koya D, Shikano T, Nakanishi S, Matsuda Y, Shigeta, Y. 1993. Antagonist for atrial natriuretic peptide receptors ameliorates glomerular hyperfiltration in diabetic rats. Biochemical and Biophysical Research Communications 193: 700-705.
Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J. 1996. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6- nephrectomized rats. Kidney International 49: 666-678.
Kondo M, Tahara A, Hayashi K, Abe M, Inami H, Ishikawa T, Ito H, Tomura Y. 2014. Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats. Naunyn- Schmiedeberg's Archives of Pharmacology 387: 909-919.
Lambers Heerspink HJ, de Zeeuw D. 2013. Novel drugs and intervention strategies for the treatment of chronic kidney disease. British Journal of Clinical Pharmacology 76: 536-550.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345: 851-860.
Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samad TA, Woolf CJ. 2006. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. The Journal of Pharmacology and Experimental Therapeutics 319: 1096-1103.
Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ. 2010. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacology and Therapeutics 128: 61–81.
Macconi D. 2010. Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histology and Histopathology 25: 655-668.
Mohamed R, Jayakumar C, Ramesh G. 2013. Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Laboratory Investigation 93: 933-945.
Murase A, Taniguchi Y, Tonai-Kachi H, Nakao K, Takeda J. 2008. In vitro pharmacological characterization of CF-042794, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Life Science 82: 226-232.
Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, Kato T, Okumura Y, Takada J. 2007. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. The Journal of Pharmacology and Experimental Therapeutics 322: 686-694.
Nangaku M. 2006. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. Journal of the American Society of Nephrology 17: 17-25.
Nangaku M, Fujita T. 2008. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertension Research 31: 175-184.
Narumiya S, Sugimoto Y, Ushikubi F. 1999. Prostanoid receptors: structures, properties, and functions. Physiological Reviews 79: 1193-226.
Nasrallah R, Hassouneh R, Hébert RL. 2016. PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes. Journal of the American Society of Nephrology 27: 666-676.
Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y. 2006. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney International 69: 1511-1517.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. 2001. Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 345: 870-878.
Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. 2005. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54: 2206- 2211.
Pöschke A, Kern N, Maruyama T, Pavenstädt H, Narumiya S, Jensen BL, Nüsing RM. 2012. The PGE2-EP4 receptor is necessary for stimulation of the renin-angiotensin- aldosterone system in response to low dietary salt intake in vivo. American Journal of Physiology Renal Physiology 503: F1435-1442.
Purdy KE, Arendshorst WJ. 2000. EP1 and EP4 receptors mediate prostaglandin E2 actions in the microcirculation of rat kidney. American Journal of Physiology 279: F755-764.
Regan, JW. 2003. EP2 and EP4 prostanoid receptor signaling. Life Science 74: 143- 153.
Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. 2006. Importance of blood pressure control in chronic kidney disease. Journal of the American Society of Nephrology 17: S98-103.
Satoh M, Kobayashi S, Kuwabara A, Tomita N, Sasaki T, Kashihara N. 2010. In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin- induced diabetic rats. Microcirculation 17: 103-112.
Schweda F, Klar J, Narumiya S, Nüsing RM, Kurtz A. 2004. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. American Journal of Physiology Renal Physiology 287: F427-433.
Sharma K, McCue P, Dunn SR. 2003. Diabetic kidney disease in the db/db mouse. American Journal of Physiology 284: F1138-1144.
Shaw JE, Sicree RA, Zimmet PZ. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87: 4-14.
Stitt-Cavanagh EM, Faour WH, Takami K, Carter A, Vanderhyden B, Guan Y, Schneider A, Breyer MD, Kennedy CR. 2010. A maladaptive role for EP4 receptors in podocytes. Journal of the American Society of Nephrology 21:1678- 1690.
Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H. 1998. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 41: 1426-1434.
Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. 2014. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin- induced type 1 diabetic rats. Journal of Pharmacy and Pharmacology 66: 975-987.
Tang L, Loutzenhiser K, Loutzenhiser R. 2000. Biphasic actions of prostaglandin E2 on the renal afferent arteriole: role of EP3 and EP4 receptors. Circulation Research 86: 663-670.
Thieme K, Majumder S, Brijmohan AS, Batchu SN, Bowskill BB, Alghamdi TA, Advani SL, Kabir MG, Liu Y, Advani A. 2017. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Scientific Reports 7: 1-11.
van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. 2010. The global burden of diabetes and its complications: an emerging pandemic. The European Journal of Cardiovascular Prevention and Rehabilitation 17: S3-8.
Vogt L, de Zeeuw D, Woittiez AJ, Navis G. 2009. Selective cyclooxygenase-2 (COX- 2) inhibition reduces proteinuria in renal patients. Nephrology Dialysis Transplantation 24: 1182-1189.
Wall EA, Zavzavadjian JR, ChangMS, Randhawa B, Zhu X, Hsueh RC, Liu J, DriverA, Bao XR, Sternweis PC, SimonMI, Fraser ID. 2009. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95- p105. Science Signaling 2: ra28 1-16.
Yang GX, Xu YY, Fan YP, Wang J, Chen XL, Zhang YD, Wu JH. 2014. A maladaptive role for EP4 receptors in mouse mesangial cells. PLoS One 9: e104091 1-13.
黒川 清. 1996. 体液異常と腎臓の病態生理. メディカル・サイエンス・インターナショナル: 1-19.
厚 生 労 働 省 . 2019. 糖 尿 病 性 腎 症 重 症 化 予 防 プ ロ グ ラ ム https://www.mhlw.go.jp/stf/houdou/0000121935_00001.html
日本腎臓学会. 2018. エビデンスに基づく CKD 診療ガイドライン https://cdn.jsn.or.jp/data/CKD2018.pdf
日本透析学会. 2018. わが国の慢性透析療法の現況. 透析会誌 51: 699-766. 槙野 博史 2000 糖尿病性腎症 診断と治療社